The role of growth factors for disease and therapy in diseases of the head and neck

DNA and Cell Biology

Volumn 22, Issue 9, 2003, Pages 593-606

  Guntinas Lichius, Orlando ^a   Wittekindt, C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BECAPLERMIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; GEFITINIB; GROWTH FACTOR; HYDROXYUREA; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; RETINOIC ACID; SEMAXANIB; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB;

ANGIOGENESIS; AUTOCRINE EFFECT; BURN; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL DIVISION; CELL PROLIFERATION; CELL PROTECTION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EAR DISEASE; EARDRUM PERFORATION; EMBRYO DEVELOPMENT; FOOT ULCER; FRACTURE HEALING; HEAD AND NECK CANCER; HEAD AND NECK DISEASE; HEARING LOSS; HUMAN; INFECTION; INNER EAR DISEASE; KERATINOCYTE; MALIGNANT NEOPLASTIC DISEASE; MITOGENESIS; MUCOSA INFLAMMATION; NERVE DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NOSE DISEASE; PARACRINE SIGNALING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SKULL DEFECT; ULCER; WOUND HEALING;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CRANIOCEREBRAL TRAUMA; GROWTH SUBSTANCES; HEAD AND NECK NEOPLASMS; HUMANS; INFECTION; MODELS, BIOLOGICAL; NECK INJURIES; NEOPLASMS; NERVE DEGENERATION; OTOLARYNGOLOGY; WOUND HEALING;

EID: 0141785519     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454903322405473     Document Type: Review

References (168)

1. Alberts DS, Noel JK. (1995). Cisplatin-associated neurotoxicity: Can it be prevented? Anticancer Drugs 6:369-383.
2. Aletsee C, Volter C, Brors D, Ryan AF, Dazert S. (2000). Effect of fibroblast growth factor-1 (FGF-1) on spiral ganglion cells of the mammalian cochlea. HNO 48:457-461.
3. Alitalo K, Carmeliet P. (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219-227.
4. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. (1997). The expanding role of nerve growth factor: From neurotrophic activity to immunologic diseases. Allergy 52:883-894.
5. Aloe L, Manni L, Properzi F, De Santis S, Fiore M. (2000). Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: Behavioral, structural and biochemical analysis. Auton Neurosci 86:84-93.
6. Amoils CP, Jackler RK, Lustig LR. (1992). Repair of chronic tympanic membrane perforations using epidermal growth factor. Otolaryngol Head Neck Surg 107:669-683.
7. Angelov DN, Skouras E, Guntinas-Lichius O, Streppel M, Popratiloff A, Walther M, Klein J, Stennert E. (1999). Contralateral trigeminal nerve lesion reduces polyneuronal muscel innervation after facial nerve repair in rats. Eur J Neurosci 11:1369-1378.
8. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ. (2000). Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284:2215-2221.
9. Bachmann G, Su J, Zumegen C, Wittekindt C, Michel O. (2001). Permeability of the round window membrane for prednisolone-21-hydrogen succinate. Prednisolone content of the perilymph after local administration vs. systemic injection. HNO 49:538-542.
10. Bange J, Zwick E, Ullrich A. (2001). Molecular targets for breast cancer therapy and prevention. Nat Med 7:548-552.
11. Barde YA. (1989). Trophic factors and neuronal survival. Neuron 2:1525-1534.
12. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Susan B, V, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. (2001). The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574.
13. Batchelor PE, Liberatore GT, Porritt MJ, Donnan GA, Howells DW. (2000). Inhibition of brain-derived neurotrophic factor and glial cell line- derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur J Neurosci 12:3462-3468.
14. Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. (2000). Design and solution structure of functional peptide mimetics of nerve growth factor. J Med Chem 43:3530-3540.
15. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U. (2-01). PDGF-D is a specific, protease-activated ligand for the PDGF beta- receptor. Nat Cell Biol 3:512-516.
16. Bier H, Hoffmann T, Haas I, van Lierop A. (1998). Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167-173.
17. Boehm-Viswanathan T. (2000). Is angiogenesis inhibition the Holy Grail of cancer therapy? Curr Opin Oncol 12:89-94.
18. Braun A, Quarcoo D, Schulte-Herbruggen O, Lommatzsch M, Hoyle G, Renz H. (2001). Nerve growth factor induces airway hyperresponsiveness in mice. Int Arch Allergy Immunol 124:205-207.
19. Brem S. (1999). Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 6:436-458.
20. Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ III, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. (1989). Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321:76-79.
21. Brown JM. (2001). Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 49:319-326.
22. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170.
23. Carmeliet P. (2000). VEGF gene therapy: Stimulating angiogenesis or angiomagenesis? Nat Med 6:1102-1103.
24. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L. (2001). Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 113:193-201.
25. Chen YS, Murakami S, Gyo K, Wakisaka H, Matsuda S, Sakanaka M. (1999). Effects of basic fibroblast growth factor (bFGF)-neutralizing antibody and platelet factor 4 on facial nerve regeneration. Exp Neurol 155:274-283.
26. Christensen ME. (1998). The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 45:121-134.
27. Coste A, Lefaucheur JP, Wang QP, Lesprit E, Poron F, Peynegre R, Escudier E. (1998). Expression of the transforming growth factor beta isoforms in inflammatory cells of nasal polyps. Arch Otolaryngol Head Neck Surg 124:1361-1366.
28. Coste A, Wang QP, Roudot-Thoraval F, Chapelin C, Bedbeder P, Poron F, Peynegre R, Escudier E. (1996). Epithelial cell proliferation in nasal polyps could be up-regulated by platelet-derived growth factor. Laryngoscope 106:578-583.
29. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A. (1998). The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 241:76-83.
30. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J. (2000). A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6:1626-1631.
31. Curnow RT. (1997). Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45:210-215.
32. Dazert S, Aletsee C, Brors D, Gravel C, Sendtner M, Ryan A. (2001). In vivo adenoviral transduction of the neonatal rat cochlea and middle ear. Hear Res 151:30-40.
33. Deplanque G, Harris AL. (2000). Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 36:1713-1724.
34. Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T. (2000). Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 22:666-673.
35. Dohm S, Streppel M, Guntinas-Lichius O, Pesheva P, Probstmeier R, Neiss WF. (2000). Identical amount of axonal branching after varying reconstructive surgery on rat facial nerve. Local application of extracellular matrix proteins fails to reduce the number of axonal branches during regeneration. Rest Neurol Neurosci 16:1-10.
36. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
37. Eatock MM, Schatzlein A, Kaye SB. (2000). Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 26:191-2-4.
38. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. (2000). Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817.
39. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST. (2000). The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89:2258-2265.
40. Ezekiel MP, Bonner JA, Robert F. (1999) Phase I trial of chimerized anti-epidermal growth factor receptor antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc Am Soc Clin Oncol 18:388a.
41. Favoni RE, de Cupis A. (2000). The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev 52:179-2-6.
42. Ferrara N. (2000). VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624.
43. Ferrara N, Alitalo K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364.
44. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. (1999). Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 88:121-125.
45. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL. (1995). Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. J Pathol 176:183-190.
46. Gasparini G. (2000). Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37-44.
47. Gasparini G, Gion M. (2000). Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints. Cancer J Sci Am 6:117-131.
48. Gerhart TN, Kirker-Head CA, Kriz MJ, Holtrop ME, Hennig GE, Hipp J, Schelling SH, Wang E. (1993). Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Aug (293):317-326.
49. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795-8800.
50. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. (2001). Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850.
51. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. (1998). Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832.
52. Guntinas-Lichius O, Angelov DN, Tomov TL, Dramiga J, Neiss WF, Wewetzer K. (2001). Transplantation of olfactory ensheathing cells stimulates the collateral sprouting from axotomized adult rat facial motoneurons. Exp Neurol 172:70-80.
53. Guntinas-Lichius O, Effenberger K, Angelov DN, Klein J, Streppel M, Stennert E, Neiss WF. (2000). Delayed rat facial nerve repair leads to accelerated and enhanced muscle reinnervation with reduced collateral axonal sprouting during a definite denervation period using a cross-anastomosis paradigm. Exp Neurol 162:98-111.
54. Guntinas-Lichius O, Wewetzer K, Tomov TL, Azzolin N, Kazemi S, Streppel M, Neiss WF, Angelov DN. (2002). Transplantation of olfactory mucosa minimizes axonal branching and promotes the recovery of vibrissae motor performance after facial nerve repair in rats. J Neurosci 22:7121-7131.
55. Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, Kiefer J, Knecht R. (2001). Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 61:1045-1049.
56. Hansson HA, Jorgensen F, Petruson B, Petruson K. (1991). Regenerating human nasal mucosa cells express peptide growth factors. Arch Otolaryngol Head Neck Surg 117:1368-1377.
57. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. (2000). Formation of endothelial cell networks. Nature 405:139-141.
58. Herbst RS, Shin DM. (2002). Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 94:1593-1611.
59. Hoffmann TK, Ballo H, Braunstein S, van Lierop A, Wagenmann M, Bier H. (2001). Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol 37:50-56.
60. Holmgren L, O'Reilly MS, Folkman J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153.
61. Hom DB. (1994). Growth factors and wound healing in otolaryngology. Otolaryngol Head Neck Surg 110:560-564.
62. Hom DB, Assefa G, Song CW. (1993). Endothelial cell growth factor (ECGF) application to irradiated soft tissue. Laryngoscope 103:165-170.
63. Hom DB, Maisel RH. (1992). Angiogenic growth factors: Their effects and potential in soft tissue wound healing. Ann Otol Rhinol Laryngol 101:349-354.
64. Hom DB, Thatcher G, Tibesar R. (2002). Growth factor therapy to improve soft tissue healing. Facial Plast Surg 18:41-52.
65. Hughes RA, Sendtner M, Thoenen H. (1993). Members of several gene families influence survival of rat motoneurons in vitro and in vivo. J Neurosci Res 36:663-671.
66. Ishimoto S, Kawamoto K, Kanzaki S, Raphael Y. (2002). Gene transfer into supporting cells of the organ of Corti. Hear Res 173:187-197.
67. Issing WJ, Heppt WJ, Kastenbauer ER. (1993). erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: Its expression in head and neck cancer cell lines. Eur Arch Otorhinolaryngol 250:392-395.
68. Issing WJ, Wustrow TP, Heppt W. (1992). Oncogenes and their significance for head and neck cancers. HNO 40:283-291.
69. Issing WJ, Wustrow TP, Heppt WJ. (1993). Oncogenes related to head and neck cancer. Anticancer Res 13:2541-2551.
70. Johnson EE, Urist MR, Finerman GA. (1992). Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop Apr (277):229-237.
71. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652.
72. Kelloff GJ, Fay JR. Steele VE, Lubet RA, Boone CW, Crowell JA, Sigman CC. (1996). Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 5:657-666.
73. Kim JS, Steck PA, Gallick GE, Lee JS, Blick M, Hong WK, Lotan R. (1992). Suppression by retinoic acid of epidermal growth factor receptor autophosphorylation and glycosylation in cultured human head and neck squamous carcinoma cells. J Natl Cancer Inst Monogr 13:101-110.
74. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24.
75. Klussmann JP, Weissenborn S, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs P. (2001). Prevalence, distribution and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92:2875-2884.
76. Knighton DR, Fiegel VD. (1993). Growth factors and comprehensive surgical care of diabetic wounds. Curr Opin Gen Surg [Review] 32-39.
77. Knipper M. (1997). NT-3 and BDNF for potential inner ear therapy. HNO 45:181-183.
78. Knox JJ, Puodziunas AL, Feld R. (2000). Chemotherapy-induced oral mucositis. Prevention and management. Drugs Aging 17:257-267.
79. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. (2001). A multi-institutional phase ii study of su 101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 7:800-805.
80. Krenz NR, Meakin SO, Krassioukov AV, Weaver LC. (1999). Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury. J Neurosci 19:7405-7414.
81. Kuang R, Hever G, Zajic G, Yah Q, Collins F, Louis JC, Keithley E, Magal E. (1999). Glial cell line-derived neurotrophic factor. Potential for otoprotection. Ann NY Acad Sci 884:270-291.
82. Kumar R, Mandal M, Vadlamudi R. (2000). New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol 27:84-91.
83. Kuntz AL, Oesterle EC. (1998). Transforming growth factor alpha with insulin stimulates cell proliferation in vivo in adult rat vestibular sensory epithelium. J Comp Neurol 399:413-423.
84. Kunz D, Walker G, Eberhardt W, Messmer UK, Huwiler A, Pfeilschifter J. (1997). Platelet-derived growth factor and fibroblast growth factor differentially regulate interleukin 1beta- and cAMP-induced nitric oxide synthase expression in rat renal mesangial cells. J Clin Invest 100:2800-2809.
85. Lammering G, Hewit TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, Valerie K, Dent P, Mikkelsen RB, Schmidt-Ullrich RK. (2001). Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93:921-929.
86. Lango MN, Shin DM, Grandis JR. (2001). Targeting growth factor receptors: Integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol 13:168-175.
87. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS. (2001). PDGF-D, a new protease-activated growth factor. Nat Cell Biol 3:517-521.
88. Lefebvre PP, Malgrange B, Staecker H, Moonen G, Van de Water TR. (1993). Retinoic acid stimulates regeneration of mammalian auditory hair cells. Science 260:692-695.
89. Levi-Montalcini R, Hamburger V. (1951). Selective growth stuimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116:321-351.
90. Lindahl T, Engel G, Ahlgren J, Klaar S, Bjohle J, Lindman H, Andersson J, von Schoultz E, Bergh J. (2000). Can axillary dissection be avoided by improved molecular biological diagnosis? Acta Oncol 39:319-326.
91. Lippman SM, Meyskens FL Jr. (1988). Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr 7:269-284.
92. Luebke AE, Foster PK, Muller CD, Peel AL. (2001). Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer. Hum Gene Ther 12:773-781.
93. Malgrange B, Rigo JM, Van de Water TR, Staecker H, Moonen G, Lefebvre PP. (1999). Growth factor therapy to the damaged inner ear: Clinical prospects. Int J Pediatr Otorhinolaryngol 49(Suppl 1):S19-S25.
94. Maran AG, Wilson JA, Gaze MN. (1993). The nature of the head and neck cancer. Eur Arch Otorhinolaryngol 250:127-132.
95. Marks PA, Richon VM, Rifkind RA. (2000). Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
96. Marsh MA, Jenkins HA, Coker NJ. (1992). Histopathology of the temporal bone following multichannel cochlear implantation. Arch Otolaryngol Head Neck Surg 118:1257-1265.
97. Marshall CJ. (1998). Signal transduction. Taking the Rap. Nature 392:553-554.
98. Marshall JS, Gomi K, Blennerhassett MG, Bienenstock J. (1999). Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism. J Immunol 162:4271-4276.
99. Marzella PL, Gillespie LN, Clark GM, Bartlett PF, Kilpatrick TJ. (1999). The neurotrophins act synergistically with LIF and members of the TGF-beta superfamily to promote the survival of spiral ganglia neurons in vitro. Hear Res 138:73-80.
100. Massague J. (1998). TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
101. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Clifford DB, Karalnik IJ. (2000). A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54:1080-1088.
102. McMahon SB, Priestley JV. (1995). Peripheral neuropathies and neurotrophic factors: Animal models and clinical perspectives. Curr Opin Neurobiol 5:616-624.
103. Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. (1999). Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci 19:3847-3859.
104. Mondain M, Ryan A. (1995). Epidermal growth factor and basic fibroblast growth factor are induced in guinea-pig tympanic membrane following traumatic perforation. Acta Otolaryngol 115:50-54.
105. Mont MA, Jones LC, Einhorn TA, Hungerford DS, Reddi AH. (1998). Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop 355:S314-S335.
106. Mori S, Fujieda S, Sunaga H, Fox SB, Saito H. (2000). Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis. Clin Exp Allergy 30:1637-1644.
107. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J. (2001). Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125-1131.
108. Murphy M, Reid K, Dutton R, Brooker G, Bartlett PF. (1997). Neural stem cells. J Investig Dermatol Symp Proc 2:8-13.
109. Mustoe TA, Purdy J, Gramates P, Deuel TF, Thomason A, Pierce GF. (1989). Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB. Am J Surg 158:345-350.
110. Nam YJ, Stover T, Hartman SS, Altschuler RA. (2000). Upregulation of glial cell line-derived neurotrophic factor (GDNF) in the rat cochlea following noise. Hear Res 146:1-6.
111. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, Burian M. (2001). Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111:1834-1841.
112. Nieder C, Nestle U. (2000). A review of current and future treatment strategies for malignant astrocytomas in adults. Strahlenther Onkol 176:251-258.
113. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL. (2000). The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36:151-169.
114. Oesterle EC, Hume CR. (1999). Growth factor regulation of the cell cycle in developing and mature inner ear sensory epithelia. J Neurocytol 28:877-887.
115. Oestreicher E, Knipper M, Arnold A, Zenner HP, Felix D. (2000). Neurotrophin 3 potentiates glutamatergic responses of IHC afferents in the cochlea in vivo. Eur J Neurosci 12:1584-1590.
116. Ostman A, Heldin CH. (2001). Involvement of platelet-derived growth factor in disease: Development of specific antagonists. Adv Cancer Res 80:1-38.
117. Pasche B. (2001). Role of transforming growth factor beta in cancer. J Cell Physiol 186:153-168.
118. Pellegrini L. (2001). Role of heparan sulfate in fibroblast growth factor signalling: A structural view. Curr Opin Struct Biol 11:629-634.
119. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C. (2000). An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 291:137-155.
120. Petruson B, Hansson HA, Petruson K. (1988). Insulinlike growth factor I immunoreactivity in nasal polyps. Arch Otolaryngol Head Neck Surg 114:1272-1275.
121. Powers MR, Qu Z, LaGesse PC, Liebler JM, Wall MA, Rosenbaum JT. (1998). Expression of basic fibroblast growth factor in nasal polyps. Ann Otol Rhinol Laryngol 107:891-897.
122. Quilitz R. (1999). Thalidomide in oncology: The peril and the promise. Cancer Control 6:483-495.
123. Quon H, Liu FF, Cummings BJ. (2001). Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 23:147-159.
124. Raivich G, Kreutzberg GW. (1993). Peripheral nerve regeneration: Role of growth factors and their receptors. Int J Dev Neurosci 11:311-324.
125. Ramsay HA, Heikkonen EJ, Laurila PK. (1995). Effect of epidermal growth factor on tympanic membranes with chronic perforations: A clinical trial. Otolaryngol Head Neck Surg 113:375-379.
126. Rihova B, Jelinkova M, Strohalm J, St'astny M, Hovorka O, Plocova D, Kovar M, Draberova L, Ulbrich K. (2000). Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene. Bioconjug Chem 11:664-673.
127. Saragovi HU, Gehring K. (2000). Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 21:93-98.
128. Sartor CI. (2000). Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family. Semin Oncol 27:15-20.
129. Schantz SP. (1994). Head and neck oncology research. Curr Opin Oncol 6:265-271.
130. Schantz SP. (1995). Basic science advances in head and neck oncology: The past decade. Semin Surg Oncol 11:272-279.
131. Schratzberger P, Schratzberger G, Silver M, Curry C, Kearney M, Magner M, Alroy J, Adelman LS, Weinberg DH, Ropper AH, Isner JM. (2000). Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6:405-413.
132. Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM, Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS. (2001). Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 24:79-87.
133. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. (1997). Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:180-186.
134. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. (2001). Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213.
135. Shoji F, Miller AL, Mitchell A, Yamasoba T, Altschuler RA, Miller JM. (2000). Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss. Hear Res 146:134-142.
136. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
137. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. (2000). Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440-1450.
138. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. (1999). Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies. Wound Repair Regen 7:335-346.
139. Smith BD, Haffty BG. (1999). Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 7:125-144.
140. Somers T, Goovaerts G, Schelfhout L, Peeters S, Govaerts PJ, Offeciers E. (1998). Growth factors in tympanic membrane perforations. Am J Otol 19:428-434.
141. Spijkervet FK, Sonis ST. (1998). New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 10(Suppl 1):S23-S27.
142. Sporn MB, Roberts AB. (1988). Peptide growth factors are multifunctional. Nature 332:217-219.
143. Sporn MB, Roberts AB (1990). Peptide Growth Factors and Their Receptors. New York: Springer Verlag.
144. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186-191.
145. Staecker H, Gabaizadeh R, Federoff H, Van de Water TR. (1998). Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol Head Neck Surg 119:7-13.
146. Staecker H, Kopke R, Malgrange B, Lefebvre P, Van de Water TR. (1996). NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells. Neuroreport 7:889-894.
147. Stennert E. (1982). The autoparalytic syndrome - A leading symptom of postparetic facial function. Arch Otorhinolaryngol 236:97-114.
148. Stover T, Nam Y, Gong TL, Lomax MI, Altschuler RA. (2001). Glial cell line-derived neurotrophic factor (GDNF) and its receptor complex are expressed in the auditory nerve of the mature rat cochlea. Hear Res 155:143-151.
149. Stover T, Yagi M, Raphael Y. (2000). Transduction of the contralateral ear after adenovirus-mediated cochlear gene transfer. Gene Ther 7:377-383.
150. Streppel M, Azzolin N, Dohm S, Guntinas-Lichius O, Haas C, Grothe C, Neiss WF, Angelov DN. (2002). Focal application of neutralizing antibodies to soluble neurotrophic factors improves the quality of axonal pathfinding after peripheral nerve lesion. Eur J Neurosci 15:1327-1342.
151. Takagi K, Urist MR. (1982). The reaction of the dura to bone morphogenetic protein (BMP) in repair of skull defects. Ann Surg 196:100-109.
152. Talks KL, Harris AL. (2000). Current status of antiangiogenic factors. Br J Haematol 109:477-489.
153. The BDNF Study Group. (1999). A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52:1427-1432.
154. Thoenen H. (1995). Neurotrophins and neuronal plasticity. Science 270:593-598.
155. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, Iwashina T, Ghahary A, Taerum TV, Scott PG. (1998). Transforming growth factor-beta in thermally injured patients with hypertrophic scars: Effects of interferon alpha-2b. Plast Reconstr Surg 102:1317-1328.
156. Tretter YP, Hertel M, Munz B, ten Bruggencate G, Werner S, Alzheimer C. (2000). Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo. Nat Med 6:812-815.
157. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. (2001). Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:2364-2373.
158. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. (1998). Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186:313-318.
159. Unsicker K, Grothe C, Westermann R, Wewetzer K. (1992). Cytokines in neural regeneration. Curr Opin Neurobiol 2:671-678.
160. Vento SI, Wolff CH, Salven PJ, Hytonen ML, Ertama LO, Malmberg CH. (2000). Vascular permeability factor/vascular endothelial growth factor in nasal polyps. Acta Otolaryngol Suppl 543:170-174.
161. Wheeler RH, Spencer S, Buchsbaum D, Robert F. (1999). Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Curr Opin Oncol 11:187-190.
162. Wiechers B, Gestwa G, Mack A, Carroll P, Zenner HP, Knipper M. (1999). A changing pattern of brain-derived neurotrophic factor expression correlates with the rearrangement of fibers during cochlear development of rats and mice. J Neurosci 19:3033-3042.
163. Wittekindt C, Hess A, Bloch W, Sultanie S, Michel O. (2002). Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol 259:294-298.
164. Wolswijk G, Noble M. (1992). Cooperation between PDGF and FGF converts slowly dividing O-2Aadult progenitor cells to rapidly dividing cells with characteristics of O-2Aperinatal progenitor cells. J Cell Biol 118:889-900.
165. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
166. Yeo SW, Kim SW, Suh BD, Cho SH. (2000). Effects of platelet-derived growth factor-AA on the healing process of tympanic membrane perforation. Am J Otolaryngol 21:153-160.
167. Zheng JL, Stewart RR, Gao WQ. (1995). Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 15:5079-5087.
168. Zine A, de Ribaupierre F. (1998). Replacement of mammalian auditory hair cells. Neuroreport 9:263-268.